Fenofibrate 130mg Capsules
Overview
What is this medicine?
How to Use This Medicine
To get the most benefit from your medication, follow your doctor's instructions carefully. Read all the information provided with your prescription and follow the instructions closely.
Some brands of this medication should be taken with food, while others can be taken with or without food. Check with your pharmacist to see if your brand needs to be taken with food. If you have difficulty swallowing, consult with your doctor.
Take your medication with a full glass of water. If you are also taking cholestyramine or colestipol, take these medications at least 4 hours before or 1 hour after your prescribed medication.
Continue taking your medication as directed by your doctor or healthcare provider, even if you start to feel better. Swallow the medication whole; do not chew, crush, open, or dissolve it.
Storing and Disposing of Your Medication
Store your medication at room temperature with the lid tightly closed. Some brands require storage in the original container, so do not remove the anti-moisture cube or packet. If you are unsure about the storage requirements for your brand, consult with your doctor or pharmacist.
What to Do If You Miss a Dose
If you miss a dose, skip it and return to your regular dosing schedule. Do not take more than one dose in a 24-hour period unless your doctor instructs you to do so.
Lifestyle & Tips
- Continue to follow a low-fat, low-cholesterol diet as recommended by your doctor or dietitian.
- Engage in regular physical activity as advised by your healthcare provider.
- Maintain a healthy weight.
- Limit alcohol intake.
- Quit smoking.
Available Forms & Alternatives
Available Strengths:
- Fenofibrate 43mg Capsules
- Fenofibrate 130mg Capsules
- Fenofibrate 130mg Capsules
- Fenofibrate 43mg Capsules
- Fenofibrate 120mg Tablets
- Fenofibrate 40mg Tablets
- Fenofibrate 50mg Capsules
- Fenofibrate 120mg Tablets
- Fenofibrate 150mg Capsules
- Fenofibrate 40mg Tablets
- Fenofibrate 145mg Tablets
- Fenofibrate 48mg Tablets
- Fenofibrate 134mg Capsules
- Fenofibrate 200mg Capsules
- Fenofibrate 67mg Capsules
- Fenofibrate 160mg Tablets
- Fenofibrate 145mg Tablets
- Fenofibrate 134mg Capsules
- Fenofibrate 54mg Tablets
- Fenofibrate 200mg Capsules
- Fenofibrate 67mg Capsules
- Fenofibrate Micro 90mg Capsules
Dosing & Administration
Adult Dosing
Condition-Specific Dosing:
Pediatric Dosing
Dose Adjustments
Renal Impairment:
Hepatic Impairment:
Pharmacology
Mechanism of Action
Pharmacokinetics
Absorption:
Distribution:
Elimination:
Pharmacodynamics
Safety & Warnings
Side Effects
Although rare, some people may experience severe and potentially life-threatening side effects while taking this medication. If you notice any of the following symptoms, contact your doctor or seek medical attention immediately:
Allergic reactions: Rash, hives, itching, red, swollen, blistered, or peeling skin with or without fever, wheezing, tightness in the chest or throat, trouble breathing, swallowing, or talking, unusual hoarseness, or swelling of the mouth, face, lips, tongue, or throat. In rare cases, allergic reactions can be life-threatening.
Liver problems: Dark urine, tiredness, decreased appetite, upset stomach or stomach pain, light-colored stools, vomiting, or yellow skin or eyes.
Pancreas problems (pancreatitis): Severe stomach pain, severe back pain, or severe upset stomach or vomiting.
Gallstones: Sudden pain in the upper right belly area, right shoulder area, or between the shoulder blades, yellow skin or eyes, or fever with chills.
Severe joint pain or swelling: Contact your doctor if you experience very bad joint pain or swelling.
Blood clots: Chest pain or pressure, coughing up blood, shortness of breath, swelling, warmth, numbness, change of color, or pain in a leg or arm, or trouble speaking or swallowing.
Muscle problems: Muscle pain or weakness, especially if you feel very tired or weak or have a fever. This can also lead to kidney problems. Inform your doctor if you have difficulty urinating or notice a change in your urine output.
Severe skin reactions: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and other serious reactions can occur, which may be life-threatening. Seek medical help immediately if you experience red, swollen, blistered, or peeling skin; red or irritated eyes; sores in your mouth, throat, nose, eyes, genitals, or any areas of skin; fever; chills; body aches; shortness of breath; or swollen glands.
Low blood cell counts: This can lead to bleeding problems, infections, or anemia. Contact your doctor if you have signs of infection, such as fever, chills, or sore throat; unexplained bruising or bleeding; or if you feel very tired or weak.
Other Side Effects
Most people do not experience significant side effects, but some may occur. If you are concerned about any of the following side effects or if they persist, contact your doctor:
Headache
Back pain
Stomach pain
This is not an exhaustive list of possible side effects. If you have questions or concerns about side effects, consult your doctor. You can also report side effects to the FDA at 1-800-332-1088 or online at https://www.fda.gov/medwatch.
Seek Immediate Medical Attention If You Experience:
- Muscle pain, tenderness, or weakness (especially if accompanied by fever or feeling unwell)
- Dark-colored urine
- Yellowing of your skin or the whites of your eyes (jaundice)
- Severe stomach pain (with or without nausea and vomiting)
- Unusual bleeding or bruising
- Swelling in your hands or feet
- Signs of an allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing)
Before Using This Medicine
It is essential to inform your doctor about the following:
Any allergies you have, including allergies to this medication, its components, or other substances. Be sure to describe the symptoms you experienced.
Certain health conditions, such as gallbladder disease, kidney disease, liver disease, or elevated liver enzymes.
If you are taking any of the following medications: atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin.
If you are breastfeeding or plan to breastfeed. Note that you should not breastfeed while taking this medication, and you may need to avoid breastfeeding for 5 days after your last dose. Consult your doctor to determine the best course of action.
Please note that this is not an exhaustive list of potential interactions. To ensure your safety, it is crucial to:
Inform your doctor and pharmacist about all medications you are taking, including prescription and over-the-counter medications, natural products, and vitamins.
Discuss all your health problems with your doctor.
Verify that it is safe to take this medication with all your other medications and health conditions.
Do not start, stop, or change the dose of any medication without first consulting your doctor.
Precautions & Cautions
Be aware that this medication can cause liver problems, which may be severe and potentially life-threatening, requiring a liver transplant or resulting in death. If you have any concerns or questions, discuss them with your doctor.
If you are 65 years or older, use this medication with caution, as you may be more susceptible to experiencing side effects.
If you are pregnant or planning to become pregnant, consult your doctor to discuss the potential benefits and risks associated with using this medication during pregnancy.
Overdose Information
Overdose Symptoms:
- No specific symptoms of overdose have been reported, but potential effects could include severe muscle pain, liver dysfunction, or kidney problems.
What to Do:
In case of suspected overdose, contact a poison control center immediately (1-800-222-1222 in the US) or seek emergency medical attention. Treatment is generally supportive and symptomatic, as fenofibric acid is highly protein bound and not effectively removed by hemodialysis.
Drug Interactions
Major Interactions
- Statins (HMG-CoA reductase inhibitors): Increased risk of myopathy/rhabdomyolysis.
- Oral anticoagulants (e.g., Warfarin): Potentiation of anticoagulant effect, increased risk of bleeding.
- Cyclosporine: Increased risk of renal dysfunction.
Moderate Interactions
- Bile acid sequestrants (e.g., Cholestyramine, Colestipol, Colesevelam): May reduce absorption of fenofibrate. Administer fenofibrate at least 1 hour before or 4-6 hours after bile acid sequestrants.
- Colchicine: Increased risk of myopathy/rhabdomyolysis.
Monitoring
Baseline Monitoring
Rationale: To establish baseline lipid levels and assess the need for therapy.
Timing: Prior to initiation of therapy.
Rationale: To assess baseline liver function, as fenofibrate can cause transaminase elevations and is contraindicated in active liver disease.
Timing: Prior to initiation of therapy.
Rationale: To assess baseline renal function, as fenofibrate is primarily renally eliminated and dose adjustments are required in renal impairment.
Timing: Prior to initiation of therapy.
Rationale: To assess for potential hematologic abnormalities, though less common.
Timing: Prior to initiation of therapy.
Routine Monitoring
Frequency: Every 4-8 weeks initially, then every 6-12 months once stable.
Target: Individualized based on treatment goals (e.g., TG < 150 mg/dL, LDL-C and HDL-C goals per guidelines).
Action Threshold: Failure to achieve lipid goals, or significant adverse changes in lipid profile.
Frequency: Every 3 months during the first year of treatment, then periodically (e.g., annually) thereafter.
Target: Within normal limits (typically < 3 times upper limit of normal).
Action Threshold: Persistent ALT/AST elevations > 3 times ULN; discontinue fenofibrate.
Frequency: Periodically, especially in elderly patients or those with pre-existing renal impairment.
Target: Stable, within acceptable limits for patient's age and baseline.
Action Threshold: Significant increase in serum creatinine or decrease in eGFR; consider dose adjustment or discontinuation.
Frequency: Periodically, if clinically indicated.
Target: Within normal limits.
Action Threshold: Significant decrease in hemoglobin, hematocrit, or white blood cell count.
Frequency: If muscle pain, tenderness, or weakness occurs.
Target: Within normal limits.
Action Threshold: Significant elevation (> 5 times ULN) or symptoms of myopathy; discontinue fenofibrate.
Symptom Monitoring
- Unexplained muscle pain, tenderness, or weakness (especially if accompanied by fever or malaise)
- Dark urine
- Yellowing of skin or eyes (jaundice)
- Severe abdominal pain (pancreatitis, gallstones)
- Nausea, vomiting, loss of appetite
- Unusual bleeding or bruising
Special Patient Groups
Pregnancy
Fenofibrate is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Trimester-Specific Risks:
Lactation
It is not known whether fenofibric acid is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Use
Safety and effectiveness in pediatric patients have not been established. Use is generally not recommended.
Geriatric Use
Use with caution in elderly patients due to the greater frequency of decreased renal function. Monitor renal function periodically. Dose adjustments may be necessary based on renal function.
Clinical Information
Clinical Pearls
- Fenofibrate should be taken with meals to optimize absorption, especially the 130mg capsule formulation.
- Regular monitoring of liver function tests (ALT/AST) and renal function (CrCl) is crucial, especially during the first year of treatment and in patients with pre-existing renal impairment.
- Patients should be advised to report any unexplained muscle pain, tenderness, or weakness immediately, as this could indicate myopathy or rhabdomyolysis, particularly when co-administered with statins.
- Fenofibrate can potentiate the effects of oral anticoagulants (e.g., warfarin), requiring careful monitoring of INR and potential dose adjustment of the anticoagulant.
- While primarily used for hypertriglyceridemia, fenofibrate also has beneficial effects on HDL-C and can reduce LDL-C, making it useful for mixed dyslipidemia.
- Contraindicated in patients with active liver disease, severe renal impairment, or pre-existing gallbladder disease.
Alternative Therapies
- Statins (e.g., Atorvastatin, Rosuvastatin, Simvastatin) - primary for LDL-C lowering, some TG lowering.
- Omega-3 Fatty Acid Esters (e.g., Icosapent ethyl, Omega-3-acid ethyl esters) - primarily for severe hypertriglyceridemia.
- Niacin (Nicotinic Acid) - for mixed dyslipidemia, but with significant side effects.
- PCSK9 Inhibitors (e.g., Alirocumab, Evolocumab) - primarily for severe hypercholesterolemia, some TG lowering.
- Bempedoic Acid - for LDL-C lowering.
- Ezetimibe - for LDL-C lowering.